Maze Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · South San Francisco, CA
MAZE chart
What traders are saying about $MAZE
Latest postsMaze Therapeutics, Inc. news
- Maze (MAZE) Slides Another -2.94% — Relief Rally Falters 2026-10-25 - Wyckoff Distribution
www.dars.gov.et ·
- Maze Therapeutics, Inc. Estimates – NASDAQ:MAZE
TradingView ·
- Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Cullinan Management (CGEM) and BeOne Medicines (ONC)
The Globe and Mail ·
- Maze Therapeutics (NasdaqGM:MAZE) Stock Forecast & Analyst Predictions
Simply Wall Street ·
- What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock
Yahoo Finance ·
- Intel upgraded, PayPal downgraded: Wall Street's top analyst calls
Yahoo Finance ·
- How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%
Yahoo Finance ·
- Pompe Disease Market Set for Expansion During the Forecast Period (2026-2036) as Growth is Fueled by Next-Generation ERTs, Newborn Screening, and Pipeline Innovation | DelveInsight
Yahoo Finance ·
- Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
Yahoo Finance ·
- 3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
marketbeat.com ·
- Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
Yahoo Finance ·
- Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?
Yahoo Finance ·
Maze Therapeutics, Inc. key financials
| USD | 2025 | 2024 |
|---|---|---|
| Revenue | – | $167.5M |
| Net income | -$131.1M | $52.2M |
| Diluted EPS | $-3.05 | $1.25 |
| Total assets (year end) | $397.1M | $240.5M |
| Cash and equivalents (year end) | $189.2M | $196.8M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Maze Therapeutics, Inc.
- Ticker
- MAZE (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- South San Francisco, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1842295
Frequently asked questions
What exchange is Maze Therapeutics, Inc. listed on?
Maze Therapeutics, Inc. trades on the Nasdaq under the ticker symbol MAZE.
What industry is Maze Therapeutics, Inc. in?
Maze Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Maze Therapeutics, Inc. headquartered?
Maze Therapeutics, Inc.'s business address on file with the SEC is in South San Francisco, CA.
When does Maze Therapeutics, Inc.'s fiscal year end?
Maze Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Maze Therapeutics, Inc. report?
Maze Therapeutics, Inc. reported $167.5M in revenue for calendar year 2024, according to its SEC filings.